Speakers - Sachs Associates

More documents

Recommendations

Info

<strong>Speakers</strong> Jason Rushton, Head of Life Sciences Advisory Initiative, Deloitte Jason leads the life science focus of Deloitte Corporate Finance in Switzerland. He has 20 years of experience in the pharmaceutical sector spanning R&D, management consulting and venture capital. Jason began his career in drug discovery with Eli Lilly and then moved to PA Consulting Group where he advised pharmaceutical /biotech clients in technical, commercial due diligence and financial transactions. For 10 years Jason was a venture capital investor with direct involvement in completing over 30 private life science transactions latterly with the venture capital fund of Nestle. Jason has been a board member of a number of biotech companies and has firsthand experience of business development and licensing. Jeremy Warren, CEO, NanoSight From a degree in Chemical Engineering from the University of Birmingham, UK, Jeremy worked for Unilever in chemical production where he qualified as a chartered engineer. He then set up a successful chemicals manufacturing business in Belgium, before completing an MBA at INSEAD in France. After a period in strategy consultancy with Booz.Allen, Warren began a series of CEO roles in SMEs centered on developing technology businesses. Warren joined NanoSight in 2005 as CEO and was directly involved in development of the company’s multiparameter characterization technology. During the last two years emphasis has been on biological nanoparticles, specifically exosomes, with particular interest in the use of NanoSight as a platform for their detection and diagnostic application to address a range of unmet need in oncology. Johanna Holldack, CEO, Telormedix S.A. Johanna has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in both startup and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene and Borean Pharma. Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School. John Burt, CEO, PolyTherics John joined PolyTherics in November 2010 and brings broad business and corporate development experience to the Company. Prior to joining PolyTherics he co-founded Thiakis, with Professor Steve Bloom (Imperial College), which he led as CEO through a major financing round in 2006 and ultimately to a very successful sale to Wyeth in 2008. John was a board member of Sterix, a joint Imperial College – University of Bath spin-out company which was acquired by Ipsen in 2004, and has been an active advisor to early-stage biotech and life sciences companies on strategy, business development and finance issues. John Trizzino, CEO, ImmunoVaccine Technologies John is a senior executive with more than 25 years of experience advancing strategic initiatives for publicly traded biotechnology companies, primarily within the vaccine market. Prior to joining Immunovaccine, he was the Senior Vice President at Novavax Inc., where he provided strategic direction and successfully negotiated profitable joint venture and licensing agreements, including a $179M BARDA contract. Prior to joining Novavax, Mr. Trizzino held senior executive positions at MedImmune Inc., which was acquired by AstraZeneca, and ID BioMedical Inc., which is now part of GlaxoSmithKline Inc. He began his extensive career in vaccines at Henry Schein Inc. leading commercial marketing efforts and executing a series of successful commercialization and distribution agreements. Mr. Trizzino is a graduate of Long Island University and received his master’s degree in business administration from New York University’s Leonard N. Stern School of Business. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
<strong>Speakers</strong> Juhani Lahdenperä, CEO, Hermo Pharma Oy Ltd Juhani as served as the Chief Executive Officer of Hermo Pharma Ltd. since February 2010. Mr. Lahdenperä holds a degree in biochemistry from the University of Oulu. Before joining Hermo Pharma Mr. Lahdenperä served as a Chief Executive Officer in Plex-Press Ltd., a gene expression analysis technology company, that he co-founded in 2006. Thus, he has 5+ years of CEO experience from VC backed organizations. Previously, he held managerial positions at the University of Helsinki and Wallac Inc. (Perkin Elmer, Inc.). Some of this work has been published in high-profile journals such as Nature. Julian Bertschinger-Ehrler, CEO and Co-Founder, Covagen Julian is co-founder and CEO of Covagen. After his studies in molecular biology and biochemistry at ETH Zurich, Julian Bertschinger joined the group of Prof. Dario Neri at the Institute of Pharmaceutical Sciences ETH Zurich as a Ph.D. student. There he co-invented Covalent DNA Display technology. After obtaining his Ph.D. in May 2005, he continued developing Covalent DNA Display as a postdoctoral fellow in Prof. Dario Neri’s group. In June 2006, Julian Bertschinger was selected from more than 100 applicants as one of the winners of the Venture Leaders Prize founded by the Gebert Rüf Stiftung. This enabled him to join a training program in the Boston area (USA) with a course in entrepreneurship at Babson College. Katya Smirnyagina, Venture Partner, Alta Partners Katya joined Alta in 2002 and focuses on European investment opportunities. She currently represents Alta on the board of directors of Cerenis Therapeutics and Kiadis Pharma. She also led Alta’s investment in Ablynx. Prior to joining Alta, she worked in business development and finance at Genset, a French genomics-based biotechnology company, where she negotiated a number of licensing agreements and strategic partnerships. Prior to Genset, Katya was a manager with the Mitchell Madison Group, a global management-consulting firm, from 1997 to 2000. She obtained a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and received her Bachelor of Science in Biochemistry with high honors from Moscow University in Russia. Katya completed her scientific training as a post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine. She has co-authored a number of scientific papers. Konstantinos Alevizoloulos, CEO, APIM Therapeutics AS Konstantinos Alevizoloulos, the current Chief Executive Officer of APIM Therapeutics AS, is a biomedical executive and enterpreneur with more than 12 years of corporate experience in the development and commercialization of novel therapeutic and diagnostic leads in the biomedical sector. He is also a partner of Ventac Partners SA, an international life science consultancy with affiliate offices in the US, Europe and Asia. Before joining APIM Therapeutics, Kostas held various executive positions including: CSO of Gerolymatos International SA (GR), CEO of Medexis SA (GR), Head of Preclinical R & D of Biovista Inc. (US) and Head of R & D of Apotech SA (CH). Dr. Alevizopoulos consults for several biotech companies, Academic Institutes and government associations; he is also a cofounder of Zestagen AG (Switzerland) and Casigen Pharma (Hong Kong). Dr. Alevizopoulos received his Biology degree from the University of Athens, Greece and his Ph.D. in Molecular Biology from the University of Lausanne, Switzerland. He has also conducted post-doctoral studies in the Swiss Institute of Experimental Cancer Research (Switzerland) and the Schering Plough Research Institute (USA) specializing in pre-clinical oncology research. Dr. Alevizopoulos is trained in European Patent Law (Robert Schuman University of Strasbourg, France). t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13: Speakers Iain Buchanan, CEO, NOXXON
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66:
CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68:
CONTACT Maaike Vogelezang Managemen
Page 69 and 70:
CONTACT Tom Johnston Chief Executiv
Page 71 and 72:
CONTACTS Aaron Powers President Dav
Page 73 and 74:
CONTACTS General and Media Contact
Page 75 and 76:
CONTACTS Martin Welschof Chief Exec
Page 77 and 78:
CONTACTS Carlos Buesa Chief Executi
Page 79 and 80:
CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?